Abstract: Provided are proteins comprising a PD-L1-binding moiety linked to a TGF?-binding moiety, IL-1-binding moiety, immunostimulatory polypeptides (e.g., soluble LAG3 or soluble CD4) or CD47-binding moiety, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.

Abstract: Anti-CLDN18.2 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the diagnostic uses thereof are provided herein.

Abstract: The present disclosure relates to an isolated PD-L1 antibody whose binding to PD-L1 at acidic pH is substantially lower than its binding to PD-L1 at neutral pH at the same assay setting and an isolated PD-L1 antibody that is not pH dependent in binding to PD-L1. Also provided is the pharmaceutical composition of the antibody, encoding polynucleotide and expression vector, isolated host cell thereof as well as a kit comprising the PD-L1 antibody. Also provided herein are methods of treating a PD-L1 associated condition using the PD-L1 antibody.

Abstract: Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.

Abstract: Provided are anti-CLDN18.2 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: The present invention relates to an anti-CD40 antibody, an antigen binding fragment and a pharmaceutical use thereof. Heavy-chain constant regions of the anti-CD40 antibody and the antigen binding fragment thereof contain mutations. Due to the mutations, the anti-CD40 antibody loses the binding activity to Fc?RIII, and the binding of the anti-CD40 antibody and Fc?RIIB is enhanced, thereby losing the antibody-dependent cytotoxicity (ADCC) but improving Fc?RIIB-mediated antibody crosslinking. The mutations in the heavy-chain constant regions enhance the activation of CD40, and enhance the presentation of dendritic cells to antigens. The anti-CD40 antibody and the antigen binding fragment thereof can be used as anti-cancer drugs to treat CD40-mediated diseases or symptoms.

Abstract: The present disclosure relates to a human IL-4R binding antibody, an antigen binding fragment thereof, and a medical use thereof. Provided are a chimeric antibody and a humanized antibody, including a CDR region from a human IL-4R binding antibody and an antigen binding fragment thereof, a pharmaceutical composition including the human IL-4R binding antibody and the antigen binding fragment thereof, and a use thereof as a drug treating allergic disease. Also provided is a use of the humanized antibody IL-4R binding antibody in preparing a drug used for treating IL-4R mediated diseases or illnesses.

Abstract: The present disclosure relates to an isolated PD-L1 antibody whose binding to PD-L1 at acidic pH is substantially lower than its binding to PD-L1 at neutral pH at the same assay setting and an isolated PD-L1 antibody that is not pH dependent in binding to PD-L1. Also provided is the pharmaceutical composition of the antibody, encoding polynucleotide and expression vector, isolated host cell thereof as well as a kit comprising the PD-L1 antibody. Also provided herein are methods of treating a PD-L1 associated condition using the PD-L1 antibody.

Abstract: An isolated PD-L1 antibody whose binding to PD-L1 at acidic pH is substantially lower than its binding to PD-L1 at neutral pH at the same assay setting and an isolated PD-L1 antibody that is not pH dependent in binding to PD-L1 are provided. The pharmaceutical composition of the antibody, encoding polynucleotide and expression vector, isolated host cell thereof as well as a kit comprising the PD-L1 antibody are also provided. Also provided herein are methods of treating a PD-L1 associated condition using the PD-L1 antibody.

Abstract: Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.

Abstract: An isolated PD-L1 antibody whose binding to PD-L1 at acidic pH is substantially lower than its binding to PD-L1 at neutral pH at the same assay setting and an isolated PD-L1 antibody that is not pH dependent in binding to PD-L1 are provided. The pharmaceutical composition of the antibody, encoding polynucleotide and expression vector, isolated host cell thereof as well as a kit comprising the PD-L1 antibody are also provided. Also provided herein are methods of treating a PD-L1 associated condition using the PD-L1 antibody.

Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Abstract: The present invention relates to binding agents for WISE, and includes methods for their manufacture and use.

Abstract: The present invention relates to binding agents for WISE, and includes for their manufacture and use.